A Phase 1/2 interventional study of CT-P6 and Herceptin in Metastatic Breast Cancer, sponsored by Celltrion. Completed at 1 site in Korea, Republic of. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-24.
Sponsored by Celltrion · Phase 1/2, Interventional, and Treatment
How we know · 8 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 618 studies in Breast Neoplasms with a site in Korea, Republic of — 132 open to participants now, 230 under way, 75 of them phase 3. Breast Neoplasms · Korea, Republic of.
Among the 618 studies in Breast Neoplasms with a site in Korea, Republic of, this one is the 316th largest by enrollment of the 505 interventional ones that give a count, is one of 22 that started in 2010, is one of 55 in phase 1/2, and was the 84th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →132 of the 618 studies in Breast Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Korea, Republic of, United States, Belgium and 5 more countries
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+ · Women only
AstraZeneca · Sites in Korea, Republic of, United States, France and 6 more countries
Ages 18–130
Novartis Pharmaceuticals · Sites in Korea, Republic of, United States, Canada and 6 more countries
Ages 18+
BeOne Medicines · Sites in Korea, Republic of, United States, Australia and 13 more countries
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
618 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 104 · Phase 2 182 · Phase 3 177 · Phase 4 14
First in 2001; this study’s year is marked. 22 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 218 across the 505 interventional studies, 444 across the 109 observational. Of the 304 that completed or were terminated, 148 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
348 of 618 have an industry lead sponsor. The 10 most frequent:
Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.
Celltrion has 2 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
44 of the studies in Breast Neoplasms with a site in Korea, Republic of that are under way reach primary completion within a year, 14 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04639986Phase 3Gilead SciencesAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | 2026-12 |
| NCT05440149Phase 3Seoul National University HospitalThe Postoperative Radiotherapy in N1 Breast Cancer Patients | 2026-12-31 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
Add all 44 to your calendar (.ics) → With an account.
Among the 618 studies in Breast Neoplasms with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to demonstrate equivalent pharmacokinetics (PK)
Patients will receive CT-P6 or Herceptin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CT-P6 was administered at a loading dose of 8 mg/kg body weight by IV infusion over 90 minutes on Day 1, Cycle 1, then at 6 mg/kg repeated at 3-weekly intervals until disease progression, death, or discontinuation. Paclitaxel was administered at a dose of 175 mg/m2 body surface area (BSA) as a continuous 3-hour IV infusion on the day following the first dose of study drug (CT-P6). If the first dose of study drug was well tolerated, subsequent doses of paclitaxel were given immediately after the next dose of study drug. Paclitaxel cycles were repeated every 3 weeks until disease progression, death, intolerable toxicity, or discontinuation.
Drug: CT-P6 · Drug: Paclitaxel
Herceptin was administered at a loading dose of 8 mg/kg body weight by IV infusion over 90 minutes on Day 1, Cycle 1, then at 6 mg/kg repeated at 3-weekly intervals until disease progression, death, or discontinuation. Paclitaxel was administered at a dose of 175 mg/m2 body surface area (BSA) as a continuous 3-hour IV infusion on the day following the first dose of study drug (Herceptin). If the first dose of study drug was well tolerated, subsequent doses of paclitaxel were given immediately after the next dose of study drug. Paclitaxel cycles were repeated every 3 weeks until disease progression, death, intolerable toxicity, or discontinuation.
Drug: Herceptin · Drug: Paclitaxel
CT-P6: administered every 3 weeks
Herceptin: administered every 3 weeks
Also known as: Trastuzumab
Paclitaxel: administered every 3 weeks
Area Under the Concentration Time Curve at Steady State (AUCss)
Area under the concentration time curve at steady state (AUCss), defined as area under the concentration-time curve between Cycle 8 to Cycle 9. The primary endpoint was reached at 6 months (8 treatment cycle; Main Study Treatment Period).
Time frame: 3, 6, 12, 24, 72, 168, 336, 504 hours predose
Trough Concentration at Steady State (CtroughSS)
Trough concentration at steady state (CtroughSS), defined as trough concentration at steady state. The secondary endpoint was reached at 6 months (8 treatment cycle; Main Study Treatment Period).
Time frame: 3, 6, 12, 24, 72, 168, 336, 504 hours predose
Cardiotoxicity
Cardiac Ejection Fraction Assessment, defined as Mean change from baseline to endpoint assessment in left ventricular ejection fraction (LVEF, Unit: %) from the independent tumor review committee (ITRC).
Time frame: Up to approximately 1 year
Immunogenicity
Immunogenicity, defined as proportion of patients with antibodies to study drug (positive for antidrug antibody \[ADA\] result after the first study infusion).
Time frame: every 4 cycles (each cycle is 3 weeks), Up to approximately 5.5 years
Overall Response Rate (ORR; Complete Response [CR] Plus Partial Response [PR]) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Overall response rate (ORR) based on best overall response (BOR) during the Main Study Treatment Period and up to 1-year treatment from the independent tumor review committee (ITRC) and Investigator. ORR (complete response \[CR\] plus partial response \[PR\]), as assessed by Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 To be assigned a best ORR of PR or CR, changes in tumour assessments must be confirmed no less than 4 weeks after the criteria for response were met.
Time frame: every 6 weeks (up to cycle 4) or 12 weeks (after cycle 4) (every cycle is 3 weeks), up to 6 months in Main treatment period and up to 1 year
Serum Human Epidermal Growth Factor Receptor-2 (HER-2) Shed Antigen Value
Serum Human epidermal growth factor receptor-2 (HER-2) shed antigen values at baseline (Cycle 1, Day 1) and the last assessments.
Time frame: day 1 of each cycle (every cycle is 3 weeks), Up to approximately 5.5 years
| Milestone | CT-P6 & Paclitaxel | Herceptin & Paclitaxel |
|---|---|---|
| Started | 76 | 67 |
| Completed | 60 | 56 |
| Not completed | 16 | 11 |
| Withdrew: Disease progression | 11 | 7 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Other reason | 0 | 1 |
| Milestone | CT-P6 & Paclitaxel | Herceptin & Paclitaxel |
|---|---|---|
| Started | 60 | 56 |
| Completed | 0 | 0 |
| Not completed | 60 | 56 |
| Withdrew: Withdrawal by subject | 4 | 4 |
| Withdrew: Physician decision | 2 | 4 |
| Withdrew: Disease progression | 51 | 45 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Other reason | 2 | 2 |
Area under the concentration time curve at steady state (AUCss), defined as area under the concentration-time curve between Cycle 8 to Cycle 9. The primary endpoint was reached at 6 months (8 treatment cycle; Main Study Treatment Period).
| ug*h/mL | CT-P6 & Paclitaxel | Herceptin & Paclitaxel |
|---|---|---|
| Area Under the Concentration Time Curve at Steady State (AUCss) | 34400 ± 15000 | 31800 ± 9820 |
Trough concentration at steady state (CtroughSS), defined as trough concentration at steady state. The secondary endpoint was reached at 6 months (8 treatment cycle; Main Study Treatment Period).
| ug/mL | CT-P6 & Paclitaxel | Herceptin & Paclitaxel |
|---|---|---|
| Trough Concentration at Steady State (CtroughSS) | 21.1 ± 7.83 | 20.8 ± 8.26 |
Cardiac Ejection Fraction Assessment, defined as Mean change from baseline to endpoint assessment in left ventricular ejection fraction (LVEF, Unit: %) from the independent tumor review committee (ITRC).
| %; percentage of LVEF | CT-P6 & Paclitaxel | Herceptin & Paclitaxel |
|---|---|---|
| Cardiotoxicity | -5.49 ± 6.543 | -6.43 ± 5.622 |
Immunogenicity, defined as proportion of patients with antibodies to study drug (positive for antidrug antibody \[ADA\] result after the first study infusion).
| Participants | CT-P6 & Paclitaxel | Herceptin & Paclitaxel |
|---|---|---|
| Immunogenicity | 2 | 0 |
Overall response rate (ORR) based on best overall response (BOR) during the Main Study Treatment Period and up to 1-year treatment from the independent tumor review committee (ITRC) and Investigator. ORR (complete response \[CR\] plus partial response \[PR\]), as assessed by Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 To be assigned a best ORR of PR or CR, changes in tumour assessments must be confirmed no less than 4 weeks after the criteria for response were met.
| percentage of responder | CT-P6 & Paclitaxel ITRC | Herceptin & Paclitaxel ITRC | CT-P6 & Paclitaxel Investigator | Herceptin & Paclitaxel Investigator |
|---|---|---|---|---|
| Main Study Treatment Period | 61.8 | 76.1 | 68.4 | 80.6 |
| 1 Year | 65.8 | 77.6 | 72.4 | 80.6 |
Serum Human epidermal growth factor receptor-2 (HER-2) shed antigen values at baseline (Cycle 1, Day 1) and the last assessments.
| ng/mL | CT-P6 & Paclitaxel | Herceptin & Paclitaxel |
|---|---|---|
| Baseline (Cycle 1, Day 1) | 85.20 ± 195.10 | 77.87 ± 169.14 |
| Last assessment | 49.68 ± 162.10 | 8.82 ± 19.97 |
Collected over Adverse event (AE) reporting extended from the date of informed consent until completion of the final visit. (Up to approximately 170 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CT-P6 & Paclitaxel | 2/76 (2.6%) | 12/76 (15.8%) | 74/76 (97.4%) |
| Herceptin & Paclitaxel | 3/67 (4.5%) | 19/67 (28.4%) | 64/67 (95.5%) |
| Event | CT-P6 & Paclitaxel | Herceptin & Paclitaxel |
|---|---|---|
| Disease progressionGeneral disorders | 1/76 | 5/67 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/76 | 3/67 |
| NeutropeniaBlood and lymphatic system disorders | 0/76 | 3/67 |
| BacteraemiaInfections and infestations | 2/76 | 0/67 |
| Back painMusculoskeletal and connective tissue disorders | 0/76 | 1/67 |
| Biliary drainageSurgical and medical procedures | 0/76 | 1/67 |
| Brain oedemaNervous system disorders | 0/76 | 1/67 |
| Cardiac failure acuteCardiac disorders | 0/76 | 1/67 |
| CholangitisHepatobiliary disorders | 0/76 | 1/67 |
| Cholecystitis acuteHepatobiliary disorders | 0/76 | 1/67 |
| Event | CT-P6 & Paclitaxel | Herceptin & Paclitaxel |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 47/76 | 44/67 |
| NeutropeniaBlood and lymphatic system disorders | 32/76 | 33/67 |
| MyalgiaMusculoskeletal and connective tissue disorders | 31/76 | 31/67 |
| Peripheral sensory neuropathyNervous system disorders | 21/76 | 27/67 |
| AstheniaGeneral disorders | 24/76 | 10/67 |
| Neuropathy peripheralNervous system disorders | 23/76 | 21/67 |
| DiarrhoeaGastrointestinal disorders | 13/76 | 18/67 |
| NauseaGastrointestinal disorders | 19/76 | 17/67 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 10/76 | 17/67 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 10/76 | 15/67 |
The Full Analysis Set (FAS) was defined as all randomized patients who received any study drug (CT-P6 or Herceptin) and had at least one post-baseline assessment, with the exception of the patients who violated against Herceptin indication.
| Age, Categorical(Participants) | CT-P6 & Paclitaxel | Herceptin & Paclitaxel | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 63 | 59 | 122 |
| >=65 years | 13 | 8 | 21 |
| Age, Continuous(years) | CT-P6 & Paclitaxel | Herceptin & Paclitaxel | Total |
|---|---|---|---|
| Mean | 55.1 ± 10.26 | 53.6 ± 10.47 | 54.4 ± 10.35 |
| Sex: Female, Male(Participants) | CT-P6 & Paclitaxel | Herceptin & Paclitaxel | Total |
|---|---|---|---|
| Female | 76 | 67 | 143 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | CT-P6 & Paclitaxel | Herceptin & Paclitaxel | Total |
|---|---|---|---|
| White | 45 | 35 | 80 |
| Asian | 31 | 32 | 63 |
| Region of Enrollment(Participants) | CT-P6 & Paclitaxel | Herceptin & Paclitaxel | Total |
|---|---|---|---|
| Bulgaria | 6 | 2 | 8 |
| South Korea | 31 | 32 | 63 |
| Latvia | 7 | 6 | 13 |
| Russia | 19 | 16 | 35 |
| Serbia | 4 | 5 | 9 |
| Ukraine | 9 | 6 | 15 |
| Childbearing potential(Participants) | CT-P6 & Paclitaxel | Herceptin & Paclitaxel | Total |
|---|---|---|---|
| Yes | 18 | 24 | 42 |
| No | 58 | 43 | 101 |
| Height at Screening(cm) | CT-P6 & Paclitaxel | Herceptin & Paclitaxel | Total |
|---|---|---|---|
| Mean | 158.9 ± 6.70 | 160.3 ± 7.20 | 159.6 ± 6.95 |
| Weight at Screening(kg) | CT-P6 & Paclitaxel | Herceptin & Paclitaxel | Total |
|---|---|---|---|
| Mean | 66.0 ± 16.64 | 67.6 ± 15.71 | 66.7 ± 16.17 |
4 further baseline measures are reported on the registry.
Ran from Feb 2010 to primary completion in Dec 2011, 22 months.
Results were first posted in Jan 2025, 13 years 1 month after primary completion.
Of 164 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 22 months is below that.
Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CT-P6